Insider Selling: Henry Schein (NASDAQ:HSIC) Director Sells 2,844 Shares of Stock

Henry Schein, Inc. (NASDAQ:HSIC) Director Kurt Kuehn sold 2,844 shares of Henry Schein stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total value of $224,562.24. Following the completion of the transaction, the director directly owned 15,420 shares of the company’s stock, valued at approximately $1,217,563.20. This trade represents a 15.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Henry Schein Trading Up 0.3%

Shares of Henry Schein stock traded up $0.21 on Wednesday, hitting $76.50. 1,060,248 shares of the company’s stock traded hands, compared to its average volume of 1,429,446. The company has a fifty day moving average of $78.23 and a two-hundred day moving average of $72.74. Henry Schein, Inc. has a one year low of $60.56 and a one year high of $89.29. The company has a market capitalization of $8.77 billion, a price-to-earnings ratio of 23.39, a price-to-earnings-growth ratio of 2.31 and a beta of 0.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.38 and a quick ratio of 0.76.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. The business had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The firm’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.19 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, sell-side analysts expect that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Wall Street Analyst Weigh In

HSIC has been the topic of several research reports. Morgan Stanley upped their price objective on shares of Henry Schein from $58.00 to $61.00 and gave the company an “underweight” rating in a report on Wednesday, February 25th. Barclays assumed coverage on Henry Schein in a research note on Monday, December 8th. They issued an “overweight” rating and a $86.00 price objective for the company. Mizuho boosted their price objective on Henry Schein from $81.00 to $88.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Wells Fargo & Company increased their target price on Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Henry Schein presently has an average rating of “Hold” and a consensus price target of $85.58.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. MAI Capital Management raised its position in Henry Schein by 7.5% in the 3rd quarter. MAI Capital Management now owns 2,061 shares of the company’s stock valued at $137,000 after buying an additional 144 shares during the last quarter. CW Advisors LLC lifted its stake in Henry Schein by 2.8% during the 2nd quarter. CW Advisors LLC now owns 5,913 shares of the company’s stock valued at $432,000 after acquiring an additional 163 shares in the last quarter. Truist Financial Corp boosted its holdings in Henry Schein by 3.3% during the 3rd quarter. Truist Financial Corp now owns 5,540 shares of the company’s stock worth $368,000 after acquiring an additional 175 shares during the last quarter. Claret Asset Management Corp boosted its holdings in Henry Schein by 6.3% during the 2nd quarter. Claret Asset Management Corp now owns 3,173 shares of the company’s stock worth $232,000 after acquiring an additional 187 shares during the last quarter. Finally, HB Wealth Management LLC grew its stake in shares of Henry Schein by 1.3% in the 4th quarter. HB Wealth Management LLC now owns 15,034 shares of the company’s stock worth $1,136,000 after acquiring an additional 191 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.